- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00237666
Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major Depression
An Open-Label, Flexible-Dose Trial of the Safety and Efficacy of Geodon in Non-Rapid-Cycling Bipolar II Patients With Major Depression
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Bipolar II disorder is largely unstudied, with much less known about its treatment in comparison to Bipolar I disorder. While established mood stabilizers treat and prevent subsequent episodes of hypomania, chronic or recurrent depressions are harder to treat or prevent. In general the treatment of depression in Bipolar II patients is often complicated and there is no clinical unanimity on what approaches to follow. Administration of proven antidepressants would seem most appropriate and are most often used, but their use often involves a number of difficulties. Among these are:
- antidepressant efficacy is established for unipolar patients and extrapolation to Bipolar II patients is done without empirical support
- Bipolar II patients can have switches into hypomanic behavior in response to antidepressant treatment given as monotherapy
- even when mood stabilizers are concomitantly given, switches to hypomanic states still occur when antidepressants are added
- antidepressants can cause cycle acceleration or induce rapid cycling when given to Bipolar II patients
- non-response and loss of response are common reactions to antidepressants in Bipolar II patients
This study will also assess the tolerability of Geodon in the treatment of patients diagnosed with Bipolar II disorder who currently meet criteria for a Major Depressive Episode by examining the incidence of adverse events and the withdrawal rate due to adverse events.
This will be an open-label study. Subjects will be treated for 8 weeks with Geodon, starting at a dose of 20 mg twice per day. The maximum dose will be 60 mg twice per day. Subjects will have a physical exam, electrocardiogram (ECG), standard laboratory tests and a urine drug screen at the screen visit.
Efficacy evaluations will include 17-item Hamilton Depression Scale, Hamilton Anxiety Scale (HAM-D), Montgomery-Asberg Depression Rating Scale, and the Young Mania Rating Scale. Social outcome will be measured with a quality-of-life scale (the Q-LES-Q). Overall efficacy will be rated using the Clinical Global Severity and Improvement Scales.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10024
- Medical Research Network, L.L.C.
-
-
Texas
-
Plano, Texas, United States, 75024
- The Mech Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients will meet DSM-IV criteria for Bipolar II Disorder, with at least one hypomanic episode as documented in the medical history or provided by an informant, or have evidence of a clear diagnosis of hypomania
- patients will currently be experiencing a major depressive episode of 2 or more weeks, but less than 12 months duration
- minimum score of 18 on the 17-item HAM-D at screen and baseline
Exclusion Criteria:
- patients will not meet criteria for Bipolar I or Schizoaffective Disorder or Schizophrenia
- patients may have co-morbid anxiety or other Axis I disorders as long as depression dominates the clinical picture
- Suicidal ideation or history that makes participation in a clinical trial unduly risky
- unstable medical conditions or any abnormality in thyroid function
- patients with a QTc of 450msec or greater on the initial ECG
- patients requiring concomitant psychotropic drugs will not be eligible, although patients on such drugs who can undergo washout will be eligible. such patients must have discontinued psychoactive drugs at least 2 weeks before beginning study, with 4 weeks for fluoxetine and depot neuroleptics
- the use of Zolpidem 5-10 mg as needed will be permitted for patients suffering from insomnia, but cannot be taken the night before a scheduled assessment
- patients with dementia or substance abuse in the last 6 months
- pregnant or lactating women will be excluded, as will those not using adequate forms of contraception
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ziprasidone
Ziprasidone monotherapy, 20-60 mg BID.
|
Ziprasidone 20-60 mg BID, taken orally.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Primary Efficacy Endpoint is the Comparison of Baseline and Week 8 Endpoint in the 17-item HAM-D Total Scores
Time Frame: Week 8
|
Hamilton Depression Rating Scale, measuring depression symptoms; possible total scores ranging from 0-54, with higher scores indicating greater severity of symptoms.
|
Week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change From Baseline in the Hamilton Anxiety Scale (HAM-A)
Time Frame: Week 8
|
Hamilton Anxiety Rating Scale, measuring anxiety symptoms; possible total scores ranging from 0-30, with higher scores indicating greater severity of anxiety.
|
Week 8
|
Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale
Time Frame: Week 8
|
Montgomery-Åsberg Depression Rating Scale, measuring depression symptoms; possible total scores ranging from 0-60, with higher scores indicating greater severity of depression.
|
Week 8
|
Percentage of Subjects With Clinical Global Inventory (CGI) Global Improvement Score of 1 or 2
Time Frame: Week 8
|
Clinical Global Impression of Improvement scale: one item, measuring overall improvement of illness; possible scores range from 1-7, with lower scores representing greater improvement. 18 subjects (60%) were responders (defined as having a CGI-I scores of 1 or 2 at Week 8/study endpoint) by the end of the trial. |
Week 8
|
Mean Change From Baseline in the CGI-Severity of Illness (CGI-S) Score at Study Endpoint
Time Frame: Week 8
|
Clinical Global Impression of Severity scale: one item, measuring overall severity of illness; possible scores range from 1-7, with higher scores representing greater severity of illness.
|
Week 8
|
Mean Change From Baseline in the Total Score of the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)
Time Frame: Week 8
|
Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) scale consists of 14 items; possible scores range from 14-70 with higher scores indicating greater quality of life and satisfaction.
|
Week 8
|
Mean Change From Baseline in the Total Score of the Beck Depression Inventory (BDI)
Time Frame: Week 8
|
Beck Depression Inventory, self-rated scale measuring depression symptoms; possible total scores ranging from 0-63, with higher scores indicating greater severity of depression.
|
Week 8
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michael R Liebowitz, MD, Medical Research Network, L.L.C.
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Mood Disorders
- Depressive Disorder
- Depression
- Depressive Disorder, Major
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Dopamine Agents
- Serotonin Antagonists
- Dopamine Antagonists
- Ziprasidone
Other Study ID Numbers
- 04-3945-A 01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Episode
-
Northside Clinic, AustraliaWesley MissionCompletedMajor Depressive EpisodeAustralia
-
University Hospital, MontpellierRecruitingMajor Depressive EpisodeFrance
-
Medical University of ViennaUnknownMajor Depressive EpisodeAustria
-
The University of New South WalesWesley MissionUnknown
-
Jiangsu Province Nanjing Brain HospitalRecruitingMajor Depressive EpisodeChina
-
Jiangsu Province Nanjing Brain HospitalRecruiting
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
University Medical Center GoettingenCompletedMajor Depressive Disorder | Depressive EpisodeGermany
-
University of British ColumbiaCentre for Addiction and Mental HealthRecruitingDepression | Major Depressive Disorder | Major Depressive EpisodeCanada
-
Milton S. Hershey Medical CenterPatient-Centered Outcomes Research Institute; Health Resources and Services...CompletedMajor Depressive Disorder | Major Depressive EpisodeUnited States
Clinical Trials on Ziprasidone
-
Donald C. Goff, MDPfizerCompletedSchizophreniaUnited States
-
Bronx Psychiatric CenterPfizer; Buffalo Psychiatric Center; Rochester Psychiatric CenterCompletedSchizophrenia | Schizoaffective DisorderUnited States
-
Yale UniversityCompleted
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedBipolar DisorderUnited States
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedBipolar DisorderUnited States
-
Dr. Reddy's Laboratories LimitedCompletedHealthyUnited States
-
Fundació Institut de Recerca de l'Hospital de la...Pfizer; Ministry of Health, Spain; REM-TAP NetworkCompletedBorderline Personality DisorderSpain
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedPsychotic Disorders | SchizophreniaTurkey, Egypt, Greece, Lebanon, Jordan, Kuwait, Saudi Arabia, South Africa, United Arab Emirates
-
Tufts Medical CenterPfizerCompletedDepression | Bipolar Disorder | Bipolar DepressionUnited States
-
Central Institute of Mental Health, MannheimCompletedSchizophrenia, Schizoaffective DisorderGermany